Cell cycle regulators, APC/β-catenin, NF-κB and EpsteinBarr virus in gastric carcinomas

Pathology

Volumn 42, Issue 1, 2010, Pages 58-65

  Kim, Bomi ^a,b,c   Byun, Sun Ju ^b   Kim, Young A ^a,b   Kim, Ji Eun ^a,b   Lee, Byung Lan ^a   Kim, Woo Ho ^a,b   Chang, Mee Soo ^a,b  

^a Seoul National University   (South Korea)

^b Department of Pathology ^*  (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

APC; B catenin; Epstein Barr virus; NF B; P21; P53; Prognosis; Stoma ch neoplasm

Indexed keywords

EID: 73649128552     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313020903356392     Document Type: Article

References (42)

1. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003; 362: 305-315
2. Plummer M, Franceschi S, Munoz N. Epidemiology of gastric cancer. IARC Sci Publ 2004; 157: 311-326
3. Headquarters of Korea Central Cancer Registry. Cancer Registry System in Korea. http://ncc.re.kr/index.jsp, accessed 2 June 2009.
4. Becker KF, Keller G, Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 2000; 9: 5-11.
5. Panani AD. Cytogenetic and molecular aspects of gastric cancer: Clinical implications. Cancer Lett 2008; 266: 99-115.
6. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumor suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003; 200: 39-46.
7. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126
8. El-Deiry WS, Tokino T, Levy DB, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825
9. Dulic V, Kaufmann WK, Wilson SJ, et al. p53 dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-1023
10. van den Berg FM, Tigges A, Schipper M, Den Hartogjager C, Kroes W, Walboomers J. Expression of the nuclear oncogene p53 in colon tumors. J Pathol 1989; 157: 193-199
11. Lane DP, Benchimol S. p53: oncogene or antioncogene? Genes Dev 1990; 4: 1-8.
12. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851
13. Barth AI, Nathke IS, Nelson WJ. Cadherins, catenins and APC protein: Interplay between cytoskeletal complexes and signaling pathway. Curr Opin Cell Biol 1997; 9: 683-690
14. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426
15. Deng J, Miller SA, Wang HY, et al. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002; 2: 323-334
16. Ougolkov A, Zhang B, Yamashita K, et al. Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst 2004; 96: 1161-1170
17. Chang MS, Lee HS, Jung EJ, Kim CW, Lee BL, Kim WH. Cell-cycle regulators, bcl-2 and NF-kappaB in Epstein-Barr virus-positive gastric carcinomas. Int J Oncol 2005; 27: 1265-1272
18. Baeuerle PA, Baltimore D. NF-kappaB: Ten years after. Cell 1996; 87: 13-20.
19. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 1993; 90: 5455-5459
20. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-456
21. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papilloma virus type 16 and 18 promotes degradation of p53. Cell 1990; 63: 1129-1136
22. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002: 99-106.
23. Lim S, Lee HS, Kim HS, Kim YI, Kim WH. Alteration of E-cadherinmediated adhesion protein is common, but microsatellite instability is uncommon in young age gastric cancers. Histopathology 2003; 42: 128-136
24. Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH. Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. Int J Cancer 2001; 95: 108-113
25. Grabsch, Takeno S, Noguchi T, Hommel G, Gabbert HE, Mueller W. Different patterns of beta-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome. Histopathology 2001; 39: 141-149
26. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in Ikappa Balpha and beta-catenin and stimulates Ikappa Balpha ubiquitination in vitro. Genes Dev 1999; 13: 270-283
27. Pinto-de-Sousa J, Silva F, David L, et al. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 2004; 44: 323-331
28. Drebber U, Baldus SE, Nolden B, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 2008; 19: 1477-1483
29. Oh SY, Kwon HC, Kim SH, et al. Clinicopathologic significance of HOF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008; 8: 123.
30. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000; 53: 255-261
31. Zhou YN, Xu CP, Han B, et al. Expression of E-cadherin and betacatenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol 2002; 8: 987-993
32. Baeza-Raja B, Munoz-Canoves P. p38 MAPK-induced nuclear factorkB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 2004; 15: 2013-2026
33. Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal antiinflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003; 362: 230-232
34. Lee HS, Chang MS, Yang HK, Lee BL, Kim WH. Epstein-Barr viruspositive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res 2004; 10: 1698-1705
35. Chang MS, Kim WH. Epstein-Barr virus in human malignancy: A special reference to Epstein-Barr Virus associated gastric carcinoma. Cancer Res Treat 2005; 37: 257-267
36. Oda K, Tamaru J, Takenouchi T, et al. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma. Am J Pathol 1993; 143: 1063-1071
37. Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993; 143: 1250-1254
38. Ojima H, Fukuda T, Nakajima T, Nagamachi Y. Infrequent overexpression of p53 protein in Epstein-Barr virus-associated gastric carcinomas. Jpn J Cancer Res 1997; 88: 262-266
39. Gulley ML, Pulitzer DR, Eagan PA, Schneider BG. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996; 27: 20-27
40. Kume T, Oshima K, Shinohara T, et al. Low rate of apoptosis and overexpression of bcl-2 in Epstein-Barr virus-associated gastric carcinoma. Histopathology 1999; 34: 502-509
41. Kang GH, Lee S, Kim WH, et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent abberant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002; 160: 787-794
42. Morrison JA, Klingelhutz AJ, Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 2003; 77: 12276-12284